Stocks and Investing Stocks and Investing
Fri, September 20, 2024
Thu, September 19, 2024
Wed, September 18, 2024
Tue, September 17, 2024

Paul Matteis Maintained (BMRN) at Strong Buy with Decreased Target to $87 on, Sep 17th, 2024


Published on 2024-10-28 14:19:22 - WOPRAI, Paul Matteis
  Print publication without navigation


Paul Matteis of Stifel, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy with Decreased Target from $115 to $87 on, Sep 17th, 2024.

Paul has made no other calls on BMRN in the last 4 months.



There are 8 other peers that have a rating on BMRN. Out of the 8 peers that are also analyzing BMRN, 2 agree with Paul's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Whitney Ijem of "Canaccord Genuity" Maintained at Hold and Held Target at $93 on, Friday, September 13th, 2024
  • Joel Beatty of "Baird" Downgraded from Buy to Hold and Decreased Target to $72 on, Friday, May 17th, 2024


These are the ratings of the 6 analyists that currently disagree with Paul


  • Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $110 on, Monday, September 9th, 2024
  • Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $122 on, Thursday, September 5th, 2024
  • Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $120 on, Thursday, September 5th, 2024
  • Cory Kasimov of "Evercore ISI Group" Maintained at Buy with Increased Target to $115 on, Tuesday, August 6th, 2024
  • Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $110 on, Tuesday, August 6th, 2024
  • Phil Nadeau of "TD Cowen" Maintained at Strong Buy with Decreased Target to $120 on, Tuesday, August 6th, 2024